Latest News
US Merck to Acquire Drugmaker Tilos Therapeutics
Tuesday 11 June 2019

11 June 2019 - US-based pharmaceutical company Merck (NYSE: MRK) has entered into a definitive agreement to acquire Tilos Therapeutics, a privately held biopharmaceutical company developing therapeutics targeting the latent TGFb complex for the treatment of cancer, fibrosis and autoimmune diseases, the company said.
Under the terms of the agreement, Merck, through a subsidiary, will acquire all outstanding shares of Tilos for total potential consideration of up to USD 773m, including an upfront payment as well as contingent milestone payments.
Tilos was founded by Boehringer Ingelheim Venture Fund and Partners Innovation Fund, based on discoveries by the laboratory of Dr. Howard Weiner at Brigham and Women's Hospital and Harvard Medical School.
Additional investment was provided by ShangPharma Innovation Fund.
TGFb is a potent cytokine believed to play an important role in the development of cancer and fibrotic diseases. TGFb is secreted as a complex with the protein, latency-associated peptide. LAP forms a cage around TGFb, holding the cytokine in an inactive state until it is deployed. E
Evidence has shown that anti-LAP antibodies block the release of TGFb from the TGFb-LAP complex with the potential to provide a novel therapeutic mechanism to reduce TGFb activity.
Date Published: 11/06/2019
Target: Tilos Therapeutics
Country: USA
Deal Size: 773m (USD)
Sector: Pharmaceuticals
Type: Corporate acquisition
Financing: Cash
Status: Agreed
Buyer: Merck